Roche broadens obesity drug plans with $1.65B Zealand deal
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.
Roche shares pop 5% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.
Roche signs biggest-ever obesity drug deal
Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from Danish biotech Zealand Pharma.
Roche, Zealand Launch Up-to-$5.3B Obesity Collaboration
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.
Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact
Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a
Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche
Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish kroner in European morning trading Wednesday,
Roche, Zealand Pharma in $5.3 Billion Pact for Obesity Drugs
Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and Eli Lilly & Co.
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
BioSpace10d
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
BioPharma Dive9d
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
Fierce Biotech1d
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
MedCity News10d
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic
The Gubra drug a peptide engineered to be an analog for amylin, a hormone that helps regulate blood sugar and food intake. It is specifically designed to bind to and activate amylin and ...
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche is stepping into the hot weight-loss drug market currently dominated by Novo Nordisk (NVO) and Eli Lilly (LLY). The ...